K. Mariën

发表

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.

F. Broeckaert, P. Meyvisch, C. Weegink, 2010, Gastroenterology.

Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers

M. Peeters, R. Hoetelmans, V. Sekar, 2007, Antiviral therapy.

Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing

P. V. Remoortere, A. Vliet, R. Verloes, 2007 .

Comparative binding and sequence interaction specificities of aflatoxin B1, aflatoxicol, aflatoxin M1, and aflatoxicol M1 with purified DNA.

K. V. van Holde, R. Moyer, P. Loveland, 1987, The Journal of biological chemistry.

Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.

A. Pozniak, R. Hoetelmans, V. Sekar, 2009, British journal of clinical pharmacology.

Site-specific aflatoxin B1 adduction of sequence-positioned nucleosome core particles.

K. V. van Holde, R. Moyer, K. Mariën, 1989, The Journal of biological chemistry.

Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

A. Hill, M. Peeters, R. Hoetelmans, 2007, British journal of clinical pharmacology.

Pharmacokinetic Interaction Between Darunavir and Saquinavir in HIV-negative Volunteers

R. Hoetelmans, V. Sekar, É. Lefebvre, 2007, Therapeutic drug monitoring.

Replication blocks and sequence interaction specificities in the codon 12 region of the c-Ha-ras proto-oncogene induced by four carcinogens in vitro.

K. V. van Holde, K. Mariën, K. Mathews, 1989, Journal of Biological Chemistry.

Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1–Infected Patients

H. Stellbrink, C. Stephan, D. Schürmann, 2014, Journal of acquired immune deficiency syndromes.